RxDoctor Payments DataLook up a doctor →

Ryan Maybrook, MD

Cardiovascular Disease · Centennial, CONPI 1780856120

Payments from drug & device makers

$10,487in general payments, 2019–2025

Across 522 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Pfizer$918
  • AstraZeneca$822
  • Heartflow, Inc.$712
  • Merck$633
  • Boston Scientific$550
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$10,01195%
  • Education$4765%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,487 in reported general payments places this provider in the 75th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$269,993
Medicare patients
1,671
Services billed
5,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban434$606,895
XareltoRivaroxaban99$132,300
Repatha SureclickEvolocumab65$52,298
EntrestoSacubitril/Valsartan34$44,982
Repatha PushtronexEvolocumab45$44,943
MultaqDronedarone Hcl20$34,876
Praluent PenAlirocumab43$30,810
JardianceEmpagliflozin20$29,919
OzempicSemaglutide26$24,147
BrilintaTicagrelor28$23,103
Nebivolol Hcl202$15,846
Repatha SyringeEvolocumab11$7,593
Dabigatran EtexilateDabigatran Etexilate Mesylate23$7,543
Metoprolol Succinate430$5,832
Rosuvastatin Calcium307$3,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$918$606,895434 claims
Johnson & JohnsonXarelto$278$132,30099 claims
NovartisEntresto$485$44,98234 claims
Sanofi-aventis U.S. LLCMultaq$511$34,87620 claims
Boehringer IngelheimJardiance$432$29,91920 claims
Novo NordiskOzempic$177$24,14726 claims
AstraZenecaBrilinta$822$23,10328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Centennial

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →